請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/42896
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 郭彥彬 | |
dc.contributor.author | Fang-Yi Wu | en |
dc.contributor.author | 吳芳儀 | zh_TW |
dc.date.accessioned | 2021-06-15T01:27:57Z | - |
dc.date.available | 2011-09-15 | |
dc.date.copyright | 2009-09-15 | |
dc.date.issued | 2009 | |
dc.date.submitted | 2009-07-22 | |
dc.identifier.citation | Notani, K., et al., A case of Sweet's syndrome (acute febrile neutrophilic dermatosis) with palatal ulceration. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2000. 89(4): p. 477-9.
2. Ko, Y.C., et al., Betel quid chewing, cigarette smoking and alcohol consumption related to oral cancer in Taiwan. J Oral Pathol Med, 1995. 24(10): p. 450-3. 3. Lippman, S.M., J. Sudbo, and W.K. Hong, Oral cancer prevention and the evolution of molecular-targeted drug development. J Clin Oncol, 2005. 23(2): p. 346-56. 4. Mao, L., W.K. Hong, and V.A. Papadimitrakopoulou, Focus on head and neck cancer. Cancer Cell, 2004. 5(4): p. 311-6. 5. Brennan, J.A., et al., Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med, 1995. 332(11): p. 712-7. 6. Wu, X., et al., Chromosome instability in lymphocytes: a potential indicator of predisposition to oral premalignant lesions. Cancer Res, 2002. 62(10): p. 2813-8. 7. Shin, S., et al., An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry, 2001. 40(4): p. 1117-23. 8. Robertson, C., What are the roles of surgery, radiation therapy and chemotherapy in the treatment of oral cancer? J Can Dent Assoc, 2006. 72(6): p. 529-30. 9. Vokes, E.E., et al., Head and neck cancer. N Engl J Med, 1993. 328(3): p. 184-94. 10. Kim, E.H., et al., Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP. Oncogene, 2004. 23(2): p. 446-56. 11. Wyllie, A.H., G.J. Beattie, and A.D. Hargreaves, Chromatin changes in apoptosis. Histochem J, 1981. 13(4): p. 681-92. 12. Loro, L.L., O.K. Vintermyr, and A.C. Johannessen, Cell death regulation in oral squamous cell carcinoma: methodological considerations and clinical significance. J Oral Pathol Med, 2003. 32(3): p. 125-38. 13. Polverini, P.J. and J.E. Nor, Apoptosis and predisposition to oral cancer. Crit Rev Oral Biol Med, 1999. 10(2): p. 139-52. 14. Singh, B.B., et al., Immunohistochemical evaluation of bcl-2 oncoprotein in oral dysplasia and carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol 1. Notani, K., et al., A case of Sweet's syndrome (acute febrile neutrophilic dermatosis) with palatal ulceration. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2000. 89(4): p. 477-9. 2. Ko, Y.C., et al., Betel quid chewing, cigarette smoking and alcohol consumption related to oral cancer in Taiwan. J Oral Pathol Med, 1995. 24(10): p. 450-3. 3. Lippman, S.M., J. Sudbo, and W.K. Hong, Oral cancer prevention and the evolution of molecular-targeted drug development. J Clin Oncol, 2005. 23(2): p. 346-56. 4. Mao, L., W.K. Hong, and V.A. Papadimitrakopoulou, Focus on head and neck cancer. Cancer Cell, 2004. 5(4): p. 311-6. 5. Brennan, J.A., et al., Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med, 1995. 332(11): p. 712-7. 6. Wu, X., et al., Chromosome instability in lymphocytes: a potential indicator of predisposition to oral premalignant lesions. Cancer Res, 2002. 62(10): p. 2813-8. 7. Shin, S., et al., An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry, 2001. 40(4): p. 1117-23. 8. Robertson, C., What are the roles of surgery, radiation therapy and chemotherapy in the treatment of oral cancer? J Can Dent Assoc, 2006. 72(6): p. 529-30. 9. Vokes, E.E., et al., Head and neck cancer. N Engl J Med, 1993. 328(3): p. 184-94. 10. Kim, E.H., et al., Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP. Oncogene, 2004. 23(2): p. 446-56. 11. Wyllie, A.H., G.J. Beattie, and A.D. Hargreaves, Chromatin changes in apoptosis. Histochem J, 1981. 13(4): p. 681-92. 12. Loro, L.L., O.K. Vintermyr, and A.C. Johannessen, Cell death regulation in oral squamous cell carcinoma: methodological considerations and clinical significance. J Oral Pathol Med, 2003. 32(3): p. 125-38. 13. Polverini, P.J. and J.E. Nor, Apoptosis and predisposition to oral cancer. Crit Rev Oral Biol Med, 1999. 10(2): p. 139-52. 14. Singh, B.B., et al., Immunohistochemical evaluation of bcl-2 oncoprotein in oral dysplasia and carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 1998. 85(6): p. 692-8. 15. Hsu, S., B. Singh, and G. Schuster, Induction of apoptosis in oral cancer cells: agents and mechanisms for potential therapy and prevention. Oral Oncol, 2004. 40(5): p. 461-73. 16. Sun, S.Y., N. Hail, Jr., and R. Lotan, Apoptosis as a novel target for cancer chemoprevention. J Natl Cancer Inst, 2004. 96(9): p. 662-72. 17. Henderson, P.J. and H.A. Lardy, Bongkrekic acid. An inhibitor of the adenine nucleotide translocase of mitochondria. J Biol Chem, 1970. 245(6): p. 1319-26. 18. Thornberry, N.A. and Y. Lazebnik, Caspases: enemies within. Science, 1998. 281(5381): p. 1312-6. 19. Ashkenazi, A. and V.M. Dixit, Death receptors: signaling and modulation. Science, 1998. 281(5381): p. 1305-8. 20. Chinnaiyan, A.M., et al., FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell, 1995. 81(4): p. 505-12. 21. Rossi, D. and G. Gaidano, Messengers of cell death: apoptotic signaling in health and disease. Haematologica, 2003. 88(2): p. 212-8. 22. Li, H., et al., Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell, 1998. 94(4): p. 491-501. 23. Luo, X., et al., Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell, 1998. 94(4): p. 481-90. 24. Li, L.Y., X. Luo, and X. Wang, Endonuclease G is an apoptotic DNase when released from mitochondria. Nature, 2001. 412(6842): p. 95-9. 25. van Loo, G., et al., Endonuclease G: a mitochondrial protein released in apoptosis and involved in caspase-independent DNA degradation. Cell Death Differ, 2001. 8(12): p. 1136-42. 26. Shimizu, S., M. Narita, and Y. Tsujimoto, Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature, 1999. 399(6735): p. 483-7. 27. Liu, X., et al., Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell, 1996. 86(1): p. 147-57. 28. Chai, J., et al., Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature, 2000. 406(6798): p. 855-62. 29. van Loo, G., et al., The serine protease Omi/HtrA2 is released from mitochondria during apoptosis. Omi interacts with caspase-inhibitor XIAP and induces enhanced caspase activity. Cell Death Differ, 2002. 9(1): p. 20-6. 30. Susin, S.A., et al., Molecular characterization of mitochondrial apoptosis-inducing factor. Nature, 1999. 397(6718): p. 441-6. 31. Adams, J.M. and S. Cory, The Bcl-2 protein family: arbiters of cell survival. Science, 1998. 281(5381): p. 1322-6. 32. Reed, J.C., J.M. Jurgensmeier, and S. Matsuyama, Bcl-2 family proteins and mitochondria. Biochim Biophys Acta, 1998. 1366(1-2): p. 127-37. 33. Li, J., A.N. Meyer, and D.J. Donoghue, Nuclear localization of cyclin B1 mediates its biological activity and is regulated by phosphorylation. Proc Natl Acad Sci U S A, 1997. 94(2): p. 502-7. 34. Zou, H., et al., An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem, 1999. 274(17): p. 11549-56. 35. Beutler, B. and C. van Huffel, Unraveling function in the TNF ligand and receptor families. Science, 1994. 264(5159): p. 667-8. 36. Schneider, P. and J. Tschopp, Apoptosis induced by death receptors. Pharm Acta Helv, 2000. 74(2-3): p. 281-6. 37. Kwon, B., B.S. Youn, and B.S. Kwon, Functions of newly identified members of the tumor necrosis factor receptor/ligand superfamilies in lymphocytes. Curr Opin Immunol, 1999. 11(3): p. 340-5. 38. Gross, A., J.M. McDonnell, and S.J. Korsmeyer, BCL-2 family members and the mitochondria in apoptosis. Genes Dev, 1999. 13(15): p. 1899-911. 39. Wallach, D., et al., Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol, 1999. 17: p. 331-67. 40. Itoh, N., et al., The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell, 1991. 66(2): p. 233-43. 41. Speiser, D.E., et al., Tumor necrosis factor receptor p55 mediates deletion of peripheral cytotoxic T lymphocytes in vivo. Eur J Immunol, 1996. 26(12): p. 3055-60. 42. Briskin, K.B., et al., Apoptotic inhibition of head and neck squamous cell carcinoma cells by tumor necrosis factor alpha. Arch Otolaryngol Head Neck Surg, 1996. 122(5): p. 559-63. 43. Seta, C., et al., Fas expression and Fas monoclonal antibody-induced apoptosis in a human squamous cell carcinoma cell line, SCC-25. J Oral Pathol Med, 2000. 29(6): p. 271-8. 44. Baker, S.J. and E.P. Reddy, Modulation of life and death by the TNF receptor superfamily. Oncogene, 1998. 17(25): p. 3261-70. 45. Fulda, S. and K.M. Debatin, Exploiting death receptor signaling pathways for tumor therapy. Biochim Biophys Acta, 2004. 1705(1): p. 27-41. 46. Liu, X., et al., Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst, 2004. 96(23): p. 1769-80. 47. Bodmer, J.L., et al., TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol, 2000. 2(4): p. 241-3. 48. Kischkel, F.C., et al., Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem, 2001. 276(49): p. 46639-46. 49. Sprick, M.R., et al., Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO J, 2002. 21(17): p. 4520-30. 50. Fanger, N.A., et al., Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med, 1999. 190(8): p. 1155-64. 51. Griffith, T.S., et al., Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med, 1999. 189(8): p. 1343-54. 52. Kayagaki, N., et al., Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity. J Immunol, 1999. 162(5): p. 2639-47. 53. Koga, Y., et al., Neutrophil-derived TNF-related apoptosis-inducing ligand (TRAIL): a novel mechanism of antitumor effect by neutrophils. Cancer Res, 2004. 64(3): p. 1037-43. 54. Nakayama, M., et al., Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity. J Exp Med, 2000. 192(9): p. 1373-80. 55. Tur, V., et al., DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design. J Biol Chem, 2008. 283(29): p. 20560-8. 56. Xia, Y., et al., JNKK1 organizes a MAP kinase module through specific and sequential interactions with upstream and downstream components mediated by its amino-terminal extension. Genes Dev, 1998. 12(21): p. 3369-81. 57. Schaeffer, H.J., et al., MP1: a MEK binding partner that enhances enzymatic activation of the MAP kinase cascade. Science, 1998. 281(5383): p. 1668-71. 58. Wada, T. and J.M. Penninger, Mitogen-activated protein kinases in apoptosis regulation. Oncogene, 2004. 23(16): p. 2838-49. 59. Lee, L.F., et al., Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK/SAPK). J Biol Chem, 1998. 273(43): p. 28253-60. 60. Boldt, S., U.H. Weidle, and W. Kolch, The role of MAPK pathways in the action of chemotherapeutic drugs. Carcinogenesis, 2002. 23(11): p. 1831-8. 61. Nguyen, T., H.C. Huang, and C.B. Pickett, Transcriptional regulation of the antioxidant response element. Activation by Nrf2 and repression by MafK. J Biol Chem, 2000. 275(20): p. 15466-73. 62. Ou, Y.C., et al., Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT. Eur J Pharmacol, 2007. 563(1-3): p. 49-60. 63. Houben, R., et al., Activation of the MAP kinase pathway induces apoptosis in the Merkel cell carcinoma cell line UISO. J Invest Dermatol, 2007. 127(9): p. 2116-22. 64. Wu, J., et al., Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res, 2004. 64(18): p. 6461-8. 65. Kaufman, R.J., Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. Genes Dev, 1999. 13(10): p. 1211-33. 66. Berridge, M.J., The endoplasmic reticulum: a multifunctional signaling organelle. Cell Calcium, 2002. 32(5-6): p. 235-49. 67. Shen, X., K. Zhang, and R.J. Kaufman, The unfolded protein response--a stress signaling pathway of the endoplasmic reticulum. J Chem Neuroanat, 2004. 28(1-2): p. 79-92. 68. Mori, K., Tripartite management of unfolded proteins in the endoplasmic reticulum. Cell, 2000. 101(5): p. 451-4. 69. Szegezdi, E., U. Fitzgerald, and A. Samali, Caspase-12 and ER-stress-mediated apoptosis: the story so far. Ann N Y Acad Sci, 2003. 1010: p. 186-94. 70. McCullough, K.D., et al., Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state. Mol Cell Biol, 2001. 21(4): p. 1249-59. 71. Murray, A.W., Recycling the cell cycle: cyclins revisited. Cell, 2004. 116(2): p. 221-34. 72. Hartwell, L.H. and T.A. Weinert, Checkpoints: controls that ensure the order of cell cycle events. Science, 1989. 246(4930): p. 629-34. 73. Peng, C.Y., et al., Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science, 1997. 277(5331): p. 1501-5. 74. Toyoshima, F., et al., Nuclear export of cyclin B1 and its possible role in the DNA damage-induced G2 checkpoint. EMBO J, 1998. 17(10): p. 2728-35. 75. Kannel, W.B., Clinical misconceptions dispelled by epidemiological research. Circulation, 1995. 92(11): p. 3350-60. 76. Keys, A., et al., The seven countries study: 2,289 deaths in 15 years. Prev Med, 1984. 13(2): p. 141-54. 77. Goldstein, J.L. and M.S. Brown, Regulation of the mevalonate pathway. Nature, 1990. 343(6257): p. 425-30. 78. Kabakoff, B.D., J.W. Doyle, and A.A. Kandutsch, Relationships among dolichyl phosphate, glycoprotein synthesis, and cell culture growth. Arch Biochem Biophys, 1990. 276(2): p. 382-9. 79. Kawata, S., et al., Increase in the active form of 3-hydroxy-3-methylglutaryl coenzyme A reductase in human hepatocellular carcinoma: possible mechanism for alteration of cholesterol biosynthesis. Cancer Res, 1990. 50(11): p. 3270-3. 80. Caruso, M.G., et al., Enhanced 3-hydroxy-3-methyl-glutaryl coenzyme A reductase activity in human colorectal cancer not expressing low density lipoprotein receptor. Anticancer Res, 1999. 19(1A): p. 451-4. 81. Littman, M.L., T. Taguchi, and E.H. Mosbach, Effect of cholesterol-free, fat-free diet and hypocholesteremic agents on growth of transplantable animal tumors. Cancer Chemother Rep, 1966. 50(1): p. 25-45. 83. Bos, J.L., ras oncogenes in human cancer: a review. Cancer Res, 1989. 49(17): p. 4682-9. 84. White, M.A., et al., Multiple Ras functions can contribute to mammalian cell transformation. Cell, 1995. 80(4): p. 533-41. 85. Casey, P.J. and M.C. Seabra, Protein prenyltransferases. J Biol Chem, 1996. 271(10): p. 5289-92. 86. Jakobisiak, M., et al., Cell cycle-specific effects of lovastatin. Proc Natl Acad Sci U S A, 1991. 88(9): p. 3628-32. 87. Kohl, N.E., et al., Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci U S A, 1994. 91(19): p. 9141-5. 88. Lin, Y.C., et al., Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2. Cancer Res, 2008. 68(7): p. 2375-83. 89. Laezza, C., et al., Lovastatin induces apoptosis of k-ras-transformed thyroid cells via inhibition of ras farnesylation and by modulating redox state. J Mol Med, 2008. 86(12): p. 1341-51. 90. Xu, C., B. Bailly-Maitre, and J.C. Reed, Endoplasmic reticulum stress: cell life and death decisions. J Clin Invest, 2005. 115(10): p. 2656-64. 91. Demierre, M.F., et al., Statins and cancer prevention. Nat Rev Cancer, 2005. 5(12): p. 930-42. 92. Wong, W.W., et al., HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia, 2002. 16(4): p. 508-19. 93. Eischen, C.M., et al., Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood, 1997. 90(3): p. 935-43. 94. Villunger, A., et al., Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Res, 1997. 57(16): p. 3331-4. 95. Jurgensmeier, J.M., et al., Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci U S A, 1998. 95(9): p. 4997-5002. 96. Shibata, M.A., et al., Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptotic mechanism. Carcinogenesis, 2004. 25(10): p. 1887-98. 97. Fan, M. and T.C. Chambers, Role of mitogen-activated protein kinases in the response of tumor cells to chemotherapy. Drug Resist Updat, 2001. 4(4): p. 253-67. 98. Cai, B., et al., p38 MAP kinase mediates apoptosis through phosphorylation of BimEL at Ser-65. J Biol Chem, 2006. 281(35): p. 25215-22. 99. Xia, Z., et al., Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science, 1995. 270(5240): p. 1326-31. 100. Goillot, E., et al., Mitogen-activated protein kinase-mediated Fas apoptotic signaling pathway. Proc Natl Acad Sci U S A, 1997. 94(7): p. 3302-7. 101. Yu, W., et al., Activation of extracellular signal-regulated kinase and c-Jun-NH(2)-terminal kinase but not p38 mitogen-activated protein kinases is required for RRR-alpha-tocopheryl succinate-induced apoptosis of human breast cancer cells. Cancer Res, 2001. 61(17): p. 6569-76. 102. Stanciu, M., et al., Persistent activation of ERK contributes to glutamate-induced oxidative toxicity in a neuronal cell line and primary cortical neuron cultures. J Biol Chem, 2000. 275(16): p. 12200-6. 103. Fukunaga, K. and E. Miyamoto, Role of MAP kinase in neurons. Mol Neurobiol, 1998. 16(1): p. 79-95. 104. Osaki, M., M. Oshimura, and H. Ito, PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis, 2004. 9(6): p. 667-76. 105. Niknejad, N., M. Morley, and J. Dimitroulakos, Activation of the integrated stress response regulates lovastatin-induced apoptosis. J Biol Chem, 2007. 282(41): p. 29748-56. 106. Bayir, H. and V.E. Kagan, Bench-to-bedside review: Mitochondrial injury, oxidative stress and apoptosis--there is nothing more practical than a good theory. Crit Care, 2008. 12(1): p. 206. 107. Packham, G. and F.K. Stevenson, Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia. Immunology, 2005. 114(4): p. 441-9. 108. Ashkenazi, A., Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer, 2002. 2(6): p. 420-30. 109. Tobert, J.A., Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov, 2003. 2(7): p. 517-26. 110. Graaf, M.R., et al., Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev, 2004. 30(7): p. 609-41. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/42896 | - |
dc.description.abstract | 口腔癌為台灣男性十大癌症發生率的第五位。也是台灣地區年增率最高的癌症。儘管近幾年口腔癌在診斷及治技術上有改進,但病人五年存活率並未有顯著改善。因此須尋找新的治療與預防方法來改善整理存活率及生活品質。Lovastatin為膽固醇合成路徑HMG-CoA reductase的抑制劑,臨床上用以降低病人高血脂。近年研究指出,lovastatin可造成大腸癌、乳癌、及頭頸癌細胞凋亡,但其機制並不十分清楚。因此本研究以人類口腔癌細胞株Ca9-22來探討它對口腔癌細胞的影響。結果顯示,以lovastatin處理Ca9-22細胞可明顯抑制其細胞生長,且濃度越高效應更加明顯。西方墨點分析顯示,以4uM的lovastatin處理Ca9-22,subG0/G1細胞數目百分比會明顯的增加,表示 lovastatin可以引起人類口腔癌細胞凋亡。西方墨點法實驗發現,在內生性凋亡路徑中,lovastatin會增加cyochrome c的釋放,以活化下游 caspase-9造成細胞凋亡。但外生性路徑之細胞膜上死亡受體 (TRAILR1、TRAILR2及FAS)皆沒有明顯改變。加入caspase-8和-9抑制劑 (Z-LEHD-FMK, Z-IETD-FMK)時,發現皆可降低lovastatin誘導細胞凋亡現象發生。當lovastatin與Z-LEHD-fmk同時處理細胞時,可減少lovastatin所造成caspase 8活化。但當lovastatin與Z-IETD-fmk同時處理細胞時,無法顯著減少lovastatin造成的caspase 9活化。 可見得內生性凋亡路徑在lovastatin所導致之細胞凋亡扮演重要角色。 我們同時發現Lovastatin處理後, 可使p-ERK、p-p38及p-JNK的表現量上升。N-acetylcysteine 及MAPK pathway抑制劑,可降低lovastatin所導致之細胞凋亡反應。MAPK在lovastatin誘發細胞凋亡中扮演角色有待進一步研究。 | zh_TW |
dc.description.abstract | Oral cancer is the fifth leading cause of cancer-related deaths in male population in Taiwan. Despite recent advances in radiotherapy and chemotherapy, the survival of patients with oral cancer has not improved significantly. Continues investigation of new chemotherapeutic agents is need. The 3-hydroxy-3-methylglutaryl coenzymeA (HMG-CoA) reductase inhibitors, also known as statins, are commonly prescribed medications that lower serum cholesterol. Preclinical research performed during the past decade shows that statins have antineoplastic effects in many tumor cell lines. Therefore, we were interested in exploring the potential of lovastatin as an anti-cancer agent in oral cancer cells. We found lovastatin significantly inhibited the cell proliferation of Ca9-22 in a dose-dependent manner. Flow cytometric analysis of DNA content showed that lovastatin treatment induced apoptosis following G1 arrest. Western blotting showed lovastatin increased cytochrome c release and activated caspase-8 and caspase-9. Caspase-9 activation is earlier than caspase-8. The apoptosis could be inhibited by caspase 8 inhibitor (Z-LEHD-FMK) or caspase 9 inhibitor (Z-IETD-FMK). These results demonstrated that the intrinsic apoptotic pathway may play a major role in the lovastatin-induced apoptosis. Pretreatment of cells with N-acetyl cysteine (NAC), MAPKs inhibitors and PI3K/Akt inhibitors inhibited the PARP cleavage. MAPKs, PI3K/Akt pathway and ROS may play important roles in lovastatin-induced apoptosis. Taking together, the chemopreventive potential of lovastatin is required to be further determined with animal model and clinical trails in the future. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T01:27:57Z (GMT). No. of bitstreams: 1 ntu-98-R96450004-1.pdf: 5940616 bytes, checksum: f5782d3c23a6f18eeb2af851c14eb1c5 (MD5) Previous issue date: 2009 | en |
dc.description.tableofcontents | 中文摘要 1
Abstract 2 第一章 導論 3 1-1 口腔癌 (Oral cancer) 3 1-2 細胞凋亡(Apoptosis) 4 1-3 細胞凋亡之分子機制 5 1-4 Bcl-2基因家族 8 1-5 TNF receptors 和death receptors 9 1-6 MAPK (Mitogen-activated protein kinase)pathway與細胞凋亡 11 1-7 內質網壓力(ER stress)與細胞凋亡 11 1-8 細胞週期 (Cell cycle) 12 1-9 Lovastatin藥物與其應用 13 1-10 Lovastatin藥理 14 1-11 Lovastatin之抗腫瘤機制 15 第二章 實驗方法與材料 17 2-1 細胞株培養 17 2-2 細胞存活率試驗 (MTT) assay 17 2-3 西方墨點法-細胞蛋白質的測定 18 2-4 Caspase抑制作用 20 2-5 其他抑制劑之抑制作用 20 2-6 分析細胞質內Cytochrome c 20 2-7 Cell death detection ELISA 21 2-8 利用Flow cytometry偵測細胞週期變化 21 2-9 利用TUNEL (Temianl deoxynucleotidyl Transferase-mediated dUTP –biotin nick end labeling)偵測細胞凋亡 22 2-10 Caspase Colorimetric Activity Assay 22 第三章 實驗結果 23 3-1、Lovastatin抑制Ca9-22細胞生長 23 3-2、Lovastatin誘導Ca9-22細胞凋亡反應 23 3-3、Lovastatin經由外在與內在凋亡路徑誘發口腔癌細胞凋亡 24 3-4、Lovastatin誘導內生性細胞凋亡 (intrinsic apoptotic pathway)機制 25 3-5、抑制死亡受體凋亡途徑對lovastatin誘導Ca9-22凋亡的影響 26 3-6、ROS (reactive oxygen species)、MAPK (Mitoge-Avtivated Protein Kinase) pathway及PI3K/Akt (Phosphatidylinositol/Akt) pathway對lovastatin誘導Ca9-22凋亡的影響 27 3-7、Lovastatin對於ER stress的影響 28 第四章 討論 29 圖與附圖 34 參考文獻 64 | |
dc.language.iso | zh-TW | |
dc.title | Lovastain誘導人類口腔癌細胞凋亡機轉之研究 | zh_TW |
dc.title | Study of Mechanism of Lovastatin-induced Apoptosis in Oral Cancer Ca9-22 cells. | en |
dc.type | Thesis | |
dc.date.schoolyear | 97-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 蕭宏昇,張正琪 | |
dc.subject.keyword | 口腔癌,lovastatin,細胞凋亡, | zh_TW |
dc.subject.keyword | Lovastatin,Aapoptosis,Oral cancer, | en |
dc.relation.page | 71 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2009-07-22 | |
dc.contributor.author-college | 牙醫專業學院 | zh_TW |
dc.contributor.author-dept | 口腔生物科學研究所 | zh_TW |
顯示於系所單位: | 口腔生物科學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-98-1.pdf 目前未授權公開取用 | 5.8 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。